Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Trulicity Summary of Product Characteristics (SmPC)
Does Trulicity® (dulaglutide) have an effect on pancreatic enzyme levels?
In the 9 registration clinical studies, dulaglutide treatment increased pancreatic enzymes. The changes in pancreatic enzymes were dose dependent and greater for dulaglutide 1.5 mg than dulaglutide 0.75 mg.
cFAQ
cFAQ
UK_cFAQ_GLP055_Z3_EFFECT_PANCREATIC_ENZYMES
en-GB
What changes in lipase and p-amylase levels were seen with dulaglutide?
The median changes in lipase ranged from
- 5.0 to 7.0 units/L with dulaglutide 1.5 mg, and
- 3.0 to 5.0 units/L with dulaglutide 0.75 mg.
Median levels in lipase also increased with sitagliptin, exenatide twice daily, and metformin. A small decrease in the median level in lipase was noted with Insulin glargine. A small decrease to no change was noted with placebo.1
The median changes in p-amylase ranged from
- 3.0 to 5.0 units/L with dulaglutide 1.5 mg, and
- 2.0 to 4.0 units/L with dulaglutide 0.75 mg.
Median levels in p-amylase also increased with sitagliptin, exenatide twice daily, metformin, and Insulin glargine. The median level in p-amylase did not change with placebo.1
References
1Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40(5):647-654. http://dx.doi.org/10.2337/dc16-0984
Date of Last Review: October 05, 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays